KEYS vs MBRX · P/E 57, rev $5.16B vs $8.2M cap
Keysight Technologies Inc (KEYS) versus Moleculin Biotech Inc (MBRX) — a side-by-side from cached financials, not a winner call.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on US.
Latest reported KEYS revenue for 2026-07-31 was $5.16B. Net income was $1.03B. Revenue was up 55.7% from 2026-04-30 to 2026-07-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Latest reported MBRX revenue for 2026-06-30 was $0. Net income was -$20.5M. MBRX currently screens at market cap $8.2M.
KEYS currently screens at market cap $59.84B and trailing P/E 56.5. MBRX currently screens at market cap $8.2M.
Not investment advice. Open the KEYS and MBRX stock pages for the full models.
Not investment advice.